Minervabiolabs/Mynox®/100200/2 treatments

TheclassicMynox®isanantibiotic-freeformulation;itsactivityisbasedonabiophysicalmechanism,thusthereisnodevelopmentofresistantstrains.Mycoplasmaarepermanentlydestroyedwithin2-3hours.

Benefits

Freeofantibiotics

RecommendedUse/Scope

Mynox®isintendedforresearchuseonly.Notapplicableforclinicaltreatment.ThedirecttreatmentofenvelopedvirusesisnotpossIBLe.

KitComponents

Mynox®isasterile,ready-to-usesolution,aliquotedpertubeforsingleuse,200µlpervial.

PackageSizes

1applicationcanbeusedtocureonecellculturepermanentlyfrommycoplasmaburden.

• Cat.No.10-02002applications
  Cat.No.10-05005applications
  Cat.No.10-100010applications

ResultEvaluation

Eliminationsuccessshouldbeverifiedwithasuitablemycoplasmadetectionsystem,e.g.MinervaBiolabs’sVenor®GeMMycoplasmaPCRDetectionKits.

RequiredConsumables

6-welltissuecultureplateorsmalltissueculturepetridish(6mmØ)
Regularcellcultureplastics

RequiredLabDevices

Regularcellcultureequipment(incubator,centrifuge,Pipettes,etc.)

ShelfLifeandStorage

Kitcomponentsaremaintainableat+2to+8°Cforatleast6months.

Fig.ElectronmicrographshowingtheeffectsofMynox®whenappliedtocontaminatedcellcultures.(A)Mycoplasmacontaminatedcellculturebeforetreatment.(B)WithoneapplicationofMynox®membranesofallmycoplasmaaredestroyedwhilethetissuecellmembraneisunaffected.Blackarrowsindicatemycoplasmas,whitearrowsindicatepartsofatissuecell.